Sermonix License Lasofoxifene to Athira

Sermonix Pharmaceuticals and Athira Pharma entered a License Agreement effective December 18, 2025. The agreement grants Athira an exclusive license to develop, manufacture, commercialize, and otherwise exploit Sermonix’s rights to Lasofoxifene and products containing Lasofoxifene outside the Retained Territory.

The exhibit text ties the licensed oncology asset to Sermonix’s selective estrogen-receptor modulator Lasofoxifene and frames Athira’s development as including additional registrational trials after a specified milestone.